Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies

Authors :: Ruiting Guo
Andreas E. Kulozik
Alexis A. Thompson
Martin Sauer
Evangelia Yannaki
Weijian Liu
John Porter
Adrian J. Thrasher
Mark C. Walters
Janet L. Kwiatkowski
Franco Locatelli
Isabelle Thuret
Richard A. Colvin
Ashutosh Lal
Suradej Hongeng
Source :: Transplantation and Cellular Therapy. 27:S112-S114
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
Transplantation
medicine.medical_specialty
business.industry
Genetic enhancement
Thalassemia
Cell Biology
Hematology
medicine.disease
Internal medicine
Transfusion dependence
Molecular Medicine
Immunology and Allergy
Medicine
business

Tools